Home Chronic Kidney Disease Complement-Mediated Disorders in Pregnancy – Advances in Chronic Kidney Disease

Complement-Mediated Disorders in Pregnancy – Advances in Chronic Kidney Disease

Credits to the Source Link Obum
Complement-Mediated Disorders in Pregnancy - Advances in Chronic Kidney Disease
  • Complement regulators and inhibitory proteins.

    Nat Rev Immunol. 2009; 9: 729-740

  • The amplification loop of the complement pathways.

    Adv Immunol. 2009; 104: 115-149

    • Manuelian T.
    • Hellwage J.
    • Meri S.
    • et al.

    Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.

    J Clin Invest. 2003; 111: 1181-1190

    • Caprioli J.
    • Noris M.
    • Brioschi S.
    • et al.

    Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

    Blood. 2006; 108: 1267-1279

    • Frémeaux-Bacchi V.
    • Miller E.C.
    • Liszewski M.K.
    • et al.

    Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.

    Blood. 2008; 112: 4948-4952

    • Ohlin A.-K.
    • Larsson K.H.M.

    Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma.

    J Thromb Haemost. 2005; 3: 976-982

    • Delvaeye M.
    • Noris M.
    • De Vriese A.
    • et al.

    Thrombomodulin mutations in atypical hemolytic-uremic syndrome.

    N Engl J Med. 2009; 361: 345-357

    • Bresin E.
    • Rurali E.
    • Caprioli J.
    • et al.

    Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

    J Am Soc Nephrol. 2013; 24: 475-486

    • Alrahmani L.
    • Willrich MA V.

    The complement alternative pathway and preeclampsia.

    Curr Hypertens Rep. 2018; 20: 40

    • Taylor C.M.
    • MacHin S.
    • Wigmore S.J.
    • Goodship T.H.J.

    Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.

    Br J Haematol. 2010; 148: 37-47

  • Pregnancy-related thrombotic microangiopathies: clues from complement biology.

    Transfus Apher Sci. 2016; 54: 199-202

    • Scully M.
    • Hunt B.J.
    • Benjamin S.
    • et al.

    Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.

    Br J Haematol. 2012; 158: 323-335

  • HUS and atypical HUS.

    Blood. 2017; 129: 2847-2857

    • Kavanagh D.
    • Richards A.
    • Atkinson J.

    Complement regulatory genes and hemolytic uremic syndromes.

    Annu Rev Med. 2008; 59: 293-309

    • Goodship T.H.J.
    • Cook H.T.
    • Fakhouri F.
    • et al.

    Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference.

    Kidney Int. 2017; 91: 539-551

    • Legendre C.M.
    • Licht C.
    • Muus P.
    • et al.

    Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome.

    NEJM. 2019; 368: 2169-2181

    • Fakhouri F.
    • Roumenina L.
    • Caillard S.
    • et al.

    Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

    J Am Soc Nephrol. 2010; 21: 859-867

    • Egbor M.
    • Johnson A.
    • Harris F.
    • Makanjoula D.
    • Shehata H.

    Pregnancy-associated atypical haemolytic uraemic syndrome in the postpartum period: a case report and review of the literature.

    Obstet Med. 2011; 4: 83-85

    • Bruel A.
    • Kavanagh D.
    • Noris M.
    • et al.

    Article hemolytic uremic syndrome in pregnancy and postpartum.

    Clin J Am Soc Nephrol. 2017; 12: 1237-1247

    • Licht C.
    • Greenbaum L.A.
    • Muus P.
    • et al.

    Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

    Kidney Int. 2015; 87: 1061-1073

  • The extended use of eculizumab in pregnancy and complement activation–associated diseases affecting maternal, fetal and neonatal kidneys-the future is now?.

    J Clin Med. 2019; 8: 407

    • Holmes C.H.
    • Simpson K.L.
    • Okada H.
    • et al.

    Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein(CD46) and decay accelerating factor (CD55).

    Eur J Immunol. 1992; 22: 1579-1585

    • Huerta A.
    • Arjona E.
    • Portoles J.
    • et al.

    A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.

    Kidney Int. 2018; 93: 450-459

    • Zuber J.
    • Fakhouri F.
    • Roumenina L.T.
    • et al.

    Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

    Nat Rev Nephrol. 2012; 8: 643-657

    • Noris M.
    • Caprioli J.
    • Bresin E.
    • et al.

    Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

    Clin J Am Soc Nephrol. 2010; 5: 1844-1859

    • Vigna E.
    • Petrungaro A.
    • Perri A.
    • et al.

    Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.

    Transfus Apher Sci. 2018; 57: 247-249

    • Burwick R.M.
    • Feinberg B.B.

    Eculizumab for the treatment of preeclampsia/HELLP syndrome.

    Placenta. 2013; 34: 201-203

    • Elabd H.
    • Elkholi M.
    • Steinberg L.
    • Acharya A.

    Eculizumab, a novel potential treatment for acute kidney injury associated with preeclampsia/HELLP syndrome.

    BMJ Case Rep. 2019; 12: e228709

    • Delmas Y.
    • Bordes C.
    • Loirat C.
    • Frémeaux-Bacchi V.
    • Combe C.

    Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice.

    Clin Kidney J. 2013; 6: 243-244

    • Servais A.
    • Devillard N.
    • Frémeaux-Bacchi V.
    • et al.

    Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.

    Nephrol Dial Transpl. 2016; 31: 2122-2130

    • Kumar D.
    • King M.
    • Jim B.
    • Acharya A.

    Recurrent case of pregnancy-induced atypical haemolytic uremic syndrome (P-aHUS).

    BMJ Case Rep. 2019; 12: e226571

    • Cheung C.
    • Nettleton K.
    • Williams M.
    • et al.

    Use of eculizumab during pregnancy in kidney transplant recipients with atypical HUS.

    Kidney Int Rep. 2019; 4: 1658

    • Kozlovskaya N.
    • Korotchaeva Y.V.
    • Bobrova L.A.

    Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis.

    J Matern Fetal Neonatal Med. 2019; 32: 2853-2859

    • Duval A.
    • Olagne J.
    • Cognard N.
    • et al.

    Pregnancy in a kidney transplant woman under treatment with eculizumab for atypical hemolytic uremic syndrome: is it safe?.

    Kidney Int Rep. 2019; 4: 733-739

    • Gupta M.
    • Govindappagari S.
    • Burwick R.

    Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review.

    Obstet Gynecol. 2020; 135: 46-58

    • Nagarajah S.
    • Tepel M.
    • Nielsen C.
    • et al.

    Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report.

    BMC Nephrol. 2019; 20: 3-7

    • Sarno L.
    • Tufano A.
    • Maruotti G.M.
    • Martinelli P.
    • Balletta M.M.
    • Russo D.

    Eculizumab in pregnancy: a narrative overview.

    J Nephrol. 2019; 32: 17-25

    • Haskin O.
    • Falush Y.
    • Davidovits M.

    Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.

    Pediatr Nephrol. 2019; 34: 2601-2604

    • Scully M.
    • Thomas M.
    • Underwood M.
    • et al.

    Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.

    Blood. 2014; 124: 211-219

    • Vesely S.K.
    • Li X.
    • McMinn J.R.
    • Terrell D.R.
    • George J.N.

    Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

    Transfusion. 2004; 44: 1149-1158

    • Mannucci P.O.
    • Canciani M.T.
    • Forza I.
    • Lussana F.
    • Lattuada A.
    • Rossi E.

    Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

    Blood. 2001; 98: 2730-2735

    • Noris M.
    • Mescia F.
    • Remuzzi G.

    STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

    Nat Rev Nephrol. 2012; 8: 622-633

  • Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von willebrand factor links complement and hemostasis-thrombosis.

    PLoS One. 2013; 8: e59372

    • Zheng L.
    • Zhang D.
    • Cao W.
    • Song W.-C.
    • Zheng X.L.

    Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.

    Blood. 2019; 134: 1095-1105

  • Current issues in chronic graft-versus-host disease.

    Blood. 2014; 124: 374-384

    • Wu T.C.
    • Yang S.
    • Haven S.
    • et al.

    Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura.

    J Thromb Haemost. 2013; 11: 1925-1927

    • Réti M.
    • Farkas P.
    • Csuka D.
    • et al.

    Complement activation in thrombotic thrombocytopenic purpura.

    J Thromb Haemost. 2012; 10: 791-798

    • Ruiz-Torres M.P.
    • Casiraghi F.
    • Galbusera M.
    • et al.

    Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.

    Thromb Haemost. 2005; 93: 443-452

    • Westwood J.P.
    • Langley K.
    • Heelas E.
    • Machin S.J.
    • Scully M.

    Complement and cytokine response in acute thrombotic thrombocytopenic purpura.

    Br J Haematol. 2014; 164: 858-866

    • Fakhouri F.
    • Vercel C.
    • Frémeaux-Bacchi V.

    Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy.

    Clin J Am Soc Nephrol. 2012; 7: 2100-2106

  • Preeclampsia: the death of goliath.

    Am J Reprod Immunol. 2006; 55: 84-98

    • Michael Holers V.
    • Girardi G.
    • Mo L.
    • et al.

    Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.

    J Exp Med. 2002; 195: 211-220

    • Davisson R.L.
    • Hoffmann D.S.
    • Butz G.M.
    • et al.

    Discovery of a spontaneous genetic mouse model of preeclampsia.

    Hypertension. 2002; 39: 337-342

    • Gelber S.E.
    • Brent E.
    • Redecha P.
    • et al.

    Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency.

    J Immunol. 2015; 195: 1129-1138

    • Burwick R.M.
    • Fichorova R.N.
    • Dawood H.Y.
    • et al.

    Urinary excretion of C5b-9 in severe preeclampsia tipping the balance of complement activation in pregnancy.

    Hypertension. 2013; 62: 1040-1045

    • Lynch A.M.
    • Gibbs R.S.
    • Murphy J.R.
    • et al.

    Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes.

    Obstet Gynecol. 2011; 117: 75-83

    • Lokki A.L.
    • Kaartokallio T.
    • Holmberg V.
    • et al.

    Analysis of complement C3 gene reveals susceptibility to severe Preeclampsia.

    Front Immunol. 2017; 8: 589

    • Cohen D.
    • Buurma A.
    • Goemaere N.N.
    • et al.

    Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss.

    J Pathol. 2011; 225: 502-511

    • Buurma A.
    • Cohen D.
    • Veraar K.
    • et al.

    Preeclampsia is characterized by placental complement dysregulation.

    Hypertension. 2012; 60: 1332-1337

    • Lynch A.M.
    • Murphy J.R.
    • Byers T.
    • et al.

    Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia.

    Am J Obstet Gynecol. 2008; 198: 385.e1-385.e9

    • Crovetto F.
    • Borsa N.
    • Acaia B.
    • et al.

    The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome.

    J Matern Neonatal Med. 2012; 25: 2322-2325

    • Salmon J.E.
    • Heuser C.
    • Triebwasser M.
    • et al.

    Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort.

    Plos Med. 2011; 8: e1001013

    • Fakhouri F.
    • Jablonski M.
    • Lepercq J.
    • et al.

    Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.

    Blood. 2008; 112: 4542-4545

    • Vaught A.J.
    • Braunstein E.M.
    • Jasem J.
    • et al.

    Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.

    JCI insight. 2018; 3: 5-7

    • Vaught A.J.
    • Gavriilaki E.
    • Hueppchen N.
    • et al.

    Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome.

    Exp Hematol. 2016; 44: 390-398

    • Berman J.
    • Girardi G.
    • Salmon J.E.

    TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss.

    J Immunol. 2005; 174: 485-490

    • Girardi G.
    • Berman J.
    • Redecha P.
    • et al.

    Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

    J Clin Invest. 2003; 112: 1644-1654

    • Qing X.
    • Redecha P.B.
    • Burmeister M.A.
    • et al.

    Targeted inhibition of complement activation prevents features of preeclampsia in mice.

    Kidney Int. 2011; 79: 331-339

    • Kim M.Y.
    • Guerra M.M.
    • Kaplowitz E.
    • et al.

    Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.

    Ann Rheum Dis. 2018; 77: 549-555

  • IMPACT study: IMProve pregnancy in APS with certolizumab therapy.

    • Clowse M.E.B.
    • Scheuerle A.E.
    • Chambers C.
    • et al.

    Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database.

    Arthritis Rheumatol. 2018; 70: 1399-1407

  • Atherosclerosis: current pathogenesis and therapeutic options.

    Nat Med. 2011; 17: 1410-1422

    • Ricklin D.
    • Hajishengallis G.
    • Yang K.
    • Lambris J.D.

    Complement: a key system for immune surveillance and homeostasis.

    Nat Immunol. 2010; 11: 785-797

    • Goicoechea de Jorge E.
    • Harris C.L.
    • Esparza-Gordillo J.
    • et al.

    Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.

    Proc Natl Acad Sci USA. 2007; 104: 240-245

    • Sallée M.
    • Daniel L.
    • Piercecchi M.D.
    • et al.

    Myocardial infarction is a complication of factor H-associated atypical HUS.

    Nephrol Dial Transpl. 2010; 25: 2028-2032

    • Venables J.P.
    • Strain L.
    • Routledge D.
    • et al.

    Atypical haemolytic uraemic syndrome associated with a hybrid complement gene.

    Plos Med. 2006; 3: 1957-1967

    • Roumenina L.T.
    • Frimat M.
    • Miller E.C.
    • et al.

    A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.

    Blood. 2012; 119: 4182-4191

    • Kichloo A.
    • Chugh S.S.
    • Gupta S.
    • Pandav J.
    • Chander P.

    Atypical hemolytic uremic syndrome presenting as acute heart failure—a rare presentation: diagnosis supported by skin biopsy.

    J Investig Med High Impact Case Rep. 2019; 7 ()

    • Kourouklaris A.
    • Ioannou K.
    • Athanasiou I.
    • Panagidou A.
    • Demetriou K.
    • Zavros M.

    Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

    J Med Case Rep. 2014; 8: 307

  • Source Link

    Related Posts

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: